Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000518879 | SCV000620916 | uncertain significance | not provided | 2018-04-18 | criteria provided, single submitter | clinical testing | The R1128K variant in the COL12A1 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. This variant is observed in 5/8616 alleles (0.058%) from individuals of East Asian background in the ExAC dataset with no homozygous control individuals reported (Lek et al., 2016) The R1128K variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. However, this substitution occurs at a position that is conserved across mammalian species, and in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. We interpret R1128K as a variant of uncertain significance. |
Invitae | RCV000802768 | SCV000942611 | likely benign | Ullrich congenital muscular dystrophy 2; Bethlem myopathy 2 | 2023-07-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002527638 | SCV003709559 | uncertain significance | Inborn genetic diseases | 2022-12-02 | criteria provided, single submitter | clinical testing | The c.3383G>A (p.R1128K) alteration is located in exon 16 (coding exon 15) of the COL12A1 gene. This alteration results from a G to A substitution at nucleotide position 3383, causing the arginine (R) at amino acid position 1128 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000518879 | SCV003833373 | uncertain significance | not provided | 2019-10-11 | criteria provided, single submitter | clinical testing |